Towards an Optimal Interval for Prostate Cancer Screening
- 31 January 2012
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 61 (1), 171-176
- https://doi.org/10.1016/j.eururo.2011.08.002
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control studyBMJ, 2010
- Mortality results from the Göteborg randomised population-based prostate-cancer screening trialThe Lancet Oncology, 2010
- A Risk-Based Strategy Improves Prostate-Specific Antigen–Driven Detection of Prostate CancerEuropean Urology, 2010
- A Framework for the Identification of Men at Increased Risk for Prostate CancerJournal of Urology, 2009
- Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)European Urology, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Interval Cancers in Prostate Cancer Screening: Comparing 2- and 4-Year Screening Intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and RotterdamJNCI Journal of the National Cancer Institute, 2007
- Methodological issues in international comparison of interval breast cancersInternational Journal of Cancer, 2006
- Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam)Urology, 2005
- Possibility of re‐screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or lessThe Prostate, 2003